Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jul 11;318(2):156-166.
doi: 10.1001/jama.2017.7967.

Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis

Jie Yu  1 , Zien Zhou  2 , R Doug McEvoy  3 , Craig S Anderson  4 , Anthony Rodgers  5 , Vlado Perkovic  5 , Bruce Neal  6
Affiliations
Meta-Analysis

Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis

Jie Yu et al. JAMA. .

Abstract

Importance: Sleep apnea (obstructive and central) is associated with adverse cardiovascular risk factors and increased risks of cardiovascular disease. Positive airway pressure (PAP) provides symptomatic relief, whether delivered continuously (CPAP) or as adaptive servo-ventilation (ASV), but the associations with cardiovascular outcomes and death are unclear.

Objective: To assess the association of PAP vs control with cardiovascular events and death in patients with sleep apnea.

Data sources and study selection: MEDLINE, EMBASE, and the Cochrane Library were systematically searched from inception date to March 2017 for randomized clinical trials that included reporting of major adverse cardiovascular events or deaths.

Data extraction and synthesis: Two authors independently extracted data using standardized forms. Summary relative risks (RRs), risk differences (RDs) and 95% CIs were obtained using random-effects meta-analysis.

Main outcomes and measures: The main outcomes were a composite of acute coronary syndrome (ACS) events, stroke, or vascular death (major adverse cardiovascular events); cause-specific vascular events; and death.

Results: The analyses included data from 10 trials (9 CPAP; 1 ASV) of patients with sleep apnea (N = 7266; mean age, 60.9 [range, 51.5 to 71.1] years; 5847 [80.5%] men; mean [SD] body mass index, 30.0 [5.2]. Among 356 major adverse cardiovascular events and 613 deaths recorded, there was no significant association of PAP with major adverse cardiovascular events (RR, 0.77 [95% CI, 0.53 to 1.13]; P = .19 and RD, -0.01 [95% CI, -0.03 to 0.01]; P = .23), cardiovascular death (RR, 1.15 [95% CI, 0.88 to 1.50]; P = .30 and RD -0.00 [95% CI, -0.02 to 0.02]; P = .87), or all-cause death (RR, 1.13 [95% CI, 0.99 to 1.29]; P = .08 and RD, 0.00 [95% CI, -0.01 to 0.01]; P = .51). The same was true for ACS, stroke, and heart failure. There was no evidence of different associations for CPAP vs ASV (all P value homogeneity >.24), and meta-regressions identified no associations of PAP with outcomes for different levels of apnea severity, follow-up duration, or adherence to PAP (all P values > .13).

Conclusions and relevance: The use of PAP, compared with no treatment or sham, was not associated with reduced risks of cardiovascular outcomes or death for patients with sleep apnea. Although there are other benefits of treatment with PAP for sleep apnea, these findings do not support treatment with PAP with a goal of prevention of these outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Anderson reports receipt of personal fees from Takeda China and Boehringer Ingelheim. Dr Perkovic reports receipt of a grant from Abbvie, Janssen, National Health and Medical Research Council of Australia (NHMRC), and Baxter; personal fees from Servier for speaking at a scientific symposia; other from Astellas, GSK, Bristol-Myers Squibb, Janssen, Boehringer Ingleheim, Pharmalink, Relypsa, Merck, Gilead, Baxter, Novartis, and Durect, as member of a steering committee or advisory board; and other from Bayer, Pfizer, Astra Zeneca, Novo Nordisk, Baker ISI, and Sanofi for speaking at a scientific symposia. Dr Neal reports receipt of a grant and personal fees from Janssen. Dr Neal (principal research), Dr Anderson (senior principal research practitioner), and Dr McEvoy (fellowship) report receipt of support from the NHMRC and being investigators on the SAVE trial (supported by grants from Philips Respironics and NHMRC [APP1060078 and APP1006501]) with supplementary grants and/or equipment from ResMed and Fisher&Paykel. No other disclosures are reported.

Figures

Figure 1.
Figure 1.. Flow Diagram of Literature Search
Figure 2.
Figure 2.. Meta-analysis of the Association of Positive Airway Pressure With Cardiovascular Events and Death
Box sizes are proportional to study weight (box center positioned at point estimate of effect). Horizontal lines indicate 95% CIs. The I2 value indicates the percentage of variability across the pooled estimates attributable to heterogeneity beyond chance (0%-25%, low likelihood; 26%-75%. moderate likelihood; 76%-100%, high likelihood), and the P value is for a test of heterogeneity across all studies (P value <.05 indicates likely variation across pooled estimates beyond chance). If 0 events were reported for 1 cell in a comparison, a value of 0.5 was added to both cells automatically before calculating the risk ratio (95% CI). Risk ratio data are rounded to 2 decimal places but plotted to exact values. aMajor adverse cardiovascular events consist of cardiovascular death, nonfatal acute coronary syndrome, and nonfatal stroke. bPlus indicates major adverse cardiovascular events in addition to hospitalization for unstable angina.
Figure 3.
Figure 3.. Meta-analysis of the Association of Positive Airway Pressure With Cardiovascular Outcomes
Box sizes are proportional to study weight (box center positioned at point estimate of effect). Horizontal lines indicate 95% CIs. The I2 value indicates the percentage of variability across the pooled estimates attributable to heterogeneity beyond chance (0%-25%, low likelihood; 26%-75%. moderate likelihood; 76%-100%, high likelihood), and the P value is for a test of heterogeneity across all studies (P value <.05 indicates likely variation across pooled estimates beyond chance). If 0 events were reported for 1 cell in a comparison, a value of 0.5 was added to both cells automatically before calculating the risk ratio (95% CI). Risk ratio data are rounded to 2 decimal places but plotted to exact values.
Figure 4.
Figure 4.. Meta-Regressions of Selected Trial Characteristics and Individual Trial Risk Ratios for Major Adverse Cardiovascular Events
A, Meta-regression of risk ratio (RR) for major adverse cardiovascular events according to length of follow-up with regression coefficient of −0.01 [95% CI, −0.04 to 0.02]; P = .52. B, Meta-regression on RR of major adverse cardiovascular events according to adherence to intervention or control with regression coefficient of −0.11 [−0.41 to 0.19]; P =.40. C, Meta-regression on RR of major adverse cardiovascular events according to apnea-hypopnea index at baseline with regression coefficient of −0.08 [−0.19 to 0.04]; P =.13. Major adverse cardiovascular events comprise cardiovascular death, nonfatal acute coronary syndrome, and nonfatal stroke. Circle sizes indicate the weight given to each study (centered on the intersection of the RR for major adverse cardiovascular events on the y-axis and the mean trial value of the metric of interest on the x-axis).
Figure 5.
Figure 5.. Association of Positive Airway Pressure With Vascular Outcomes and Deaths in Trial Subgroups
Box sizes are proportional to study weight (box center positioned at point estimate of effect). The I2 value indicates the percentage of variability across the pooled estimates attributable to heterogeneity beyond chance (0%-25%, low likelihood; 26%-75%, moderate likelihood; 76%-100%, high likelihood), and the P value is for a test of heterogeneity across all studies. Abbreviations: ASV, adaptive servo-ventilation; CPAP, continuous positive airway pressure; CSA, central sleep apnea; OSA: obstructive sleep apnea; PAP, positive airway pressure. aMajor adverse cardiovascular events comprise cardiovascular death, nonfatal acute coronary syndrome, and nonfatal stroke. bPlus indicates major adverse cardiovascular events in addition to hospitalization for unstable angina.
See this image and copyright information in PMC

Comment in

References

    1. Marin JM, Agusti A, Villar I, et al. . Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA. 2012;307(20):2169-2176. - PMC - PubMed
    1. Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia—revisited—the bad ugly and good. Sleep Med Rev. 2015;20:27-45. - PubMed
    1. Phillips CL, McEwen BJ, Morel-Kopp MC, et al. . Effects of continuous positive airway pressure on coagulability in obstructive sleep apnoea. Thorax. 2012;67(7):639-644. - PubMed
    1. Somers VK, White DP, Amin R, et al. . Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol. 2008;52(8):686-717. - PubMed
    1. Buchanan P, Grunstein R. Positive airway pressure treatment for obstructive sleep apnea-hypopnea syndrome In: Kryger MH, Roth T, Dement WC In: Principles and Practice of Sleep Medicine. 5th ed Philadelphia, PA: Elsevier Saunders; 2011:1233-1249

MeSH terms